Congressional Problem Solvers Caucus Endorses RESULTS Act
A bipartisan congressional caucus recently announced its endorsement of the Reforming and Enhancing Sustainable Updates to Laboratory Testing...
The U.S. Food and Drug Administration (FDA) formally rescinded its final rule regulating laboratory-developed tests as medical devices, and regulatory review is now pending. Because the FDA did not move to appeal this decision, the rescission is essentially a formality.
The recission comes following the decision filed March 31 in the U.S. District Court in the Eastern District of Texas, which ruled the FDA exceeded its authority and subsequently vacated the final rule. The FDA did not appeal this decision.
Once the Office of Information and Regulatory Affairs completes the regulatory review, a formal notice will be posted to the Federal Register within 60 days.
Sources:
https://www.reginfo.gov/public/do/eoDetails?rrid=1044563
https://documents.cap.org/documents/ldt-courtruling-03-31-2025.pdf
https://www.cap.org/advocacy/latest-news-and-practice-data/august-12-2025#story3
Senate HELP Committee Votes to Advance Price Transparency Legislation
On July 22, the Senate Health, Education, Labor, and Pensions (HELP) Committee voted to advance the Patients Deserve Price Tags Act (S.2355) by a...
The Rise of CLIA-Related Rejections: What Labs Should Review
Since CMS transitioned CLIA certification to a paperless system in March, TELCOR has noticed an increase in CLIA-related rejections and denials from...